Positive new Ph III data for ACADIA Pharma’s pimavanserin in Parkinson’s

1 November 2013

US biotech firm ACADIA Pharmaceuticals (Nasdaq: ACAD) says that new date published in the on-line edition of The Lancet today (November 1) from its pivotal Phase III -020 Study with pimavanserin in patients with Parkinson’s disease psychosis (PDP) demonstrated significant and clinically meaningful benefits and showed the drug was safe and well tolerated in patients with PDP.

Pimavanserin significantly reduced psychosis and maintained motor control in patients with PDP. Significant benefits were also observed in exploratory measures of night-time sleep, daytime wakefulness and caregiver burden.

Earlier this year, the Food and Drug Administration agreed that the data from the pivotal Phase III -020 study, together with supportive data from other studies with pimavanserin, are sufficient to support the filing of a New Drug Application for the treatment of Parkinson’s disease psychosis (PDP; The Pharma Letter April 11). Pimavanserin is partnered with Canadian biotechnology firm Biovail (TSE: BVF) under a deal which could earn the US group as much as $395.0 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK